Archives
Staurosporine: Broad-Spectrum Serine/Threonine Protein Ki...
Staurosporine: Broad-Spectrum Serine/Threonine Protein Kinase Inhibitor for Tumor Research
Executive Summary: Staurosporine (CAS 62996-74-1) is a potent alkaloid inhibitor of serine/threonine protein kinases, originally isolated from Streptomyces staurospores and supplied by APExBIO (SKU: A8192) [link]. It inhibits protein kinase C (PKC) isoforms with nanomolar IC50 values (PKCα: 2 nM; PKCγ: 5 nM; PKCη: 4 nM), as well as PKA, EGF-R kinase, CaMKII, and S6 kinase. Staurosporine blocks ligand-induced autophosphorylation of VEGF, PDGF, and c-Kit receptors (IC50 values: 0.08–1.0 mM in cell-based assays), but does not affect insulin, IGF-I, or EGF receptor autophosphorylation. It is widely used to induce apoptosis in mammalian cancer cell lines and to model anti-angiogenic mechanisms in tumor research [DOI]. Animal studies confirm its anti-angiogenic and anti-metastatic effects at 75 mg/kg/day (oral), making it central to cancer biology and translational workflows.
Biological Rationale
Protein kinases regulate cell signaling, proliferation, survival, and apoptosis. Dysregulation of kinase activity is a hallmark of cancer and other diseases. Inhibitors such as Staurosporine enable precise dissection of kinase-dependent pathways. Staurosporine’s broad-spectrum inhibition profile allows it to interrogate the roles of PKC, PKA, CaMKII, and receptor tyrosine kinases in cellular processes. It is especially powerful in cancer models where apoptosis induction and angiogenesis inhibition are key research endpoints [see detailed mechanistic overview]. This article updates and extends prior reviews by providing atomic, verifiable data on activity, selectivity, and workflow integration for Staurosporine (SKU A8192).
Mechanism of Action of Staurosporine
Staurosporine is an indolocarbazole alkaloid. It competitively binds the ATP-binding sites of serine/threonine and select tyrosine kinases. Its inhibition constants (IC50) for PKC isoforms are in the low nanomolar range (PKCα: 2 nM, PKCγ: 5 nM, PKCη: 4 nM; measured in kinase assays at 30°C, pH 7.5, 10 mM MgCl₂) [APExBIO]. Staurosporine also inhibits PKA, EGF-R kinase, CaMKII, phosphorylase kinase, and S6 kinase, with variable potencies (IC50 values typically 2–20 nM). In cell models, it blocks ligand-induced autophosphorylation of VEGF receptor KDR (IC50 = 1.0 mM, CHO-KDR cells), PDGF receptor (IC50 = 0.08 mM, A31 cells), and c-Kit (IC50 = 0.30 mM, Mo-7e cells). Importantly, it does not inhibit insulin, IGF-I, or EGF receptor autophosphorylation, indicating selectivity in receptor context. These actions collectively disrupt survival pathways and trigger apoptosis, particularly in tumor cell lines.
Evidence & Benchmarks
- Staurosporine induces apoptosis in a wide range of mammalian cancer cell lines, including A431, THP-1, and Mo-7e, within 24 hours at nanomolar concentrations (0.1–1 μM) (Gonzalez-Martinez et al., 2025, https://doi.org/10.1039/d5lp00131e).
- In animal models, oral administration at 75 mg/kg/day significantly inhibits VEGF-induced angiogenesis via VEGF-R KDR and PKC blockade (APExBIO product data, https://www.apexbt.com/staurosporine.html).
- Staurosporine’s IC50 values for PKC isoforms are 2 nM (PKCα), 4 nM (PKCη), and 5 nM (PKCγ) in in vitro kinase assays (APExBIO, link).
- It inhibits PDGF receptor autophosphorylation (IC50 = 0.08 mM, A31 cells) but not insulin receptor signaling, supporting its use in dissecting specific kinase pathways (APExBIO, link).
- Staurosporine is insoluble in water and ethanol, but highly soluble in DMSO (≥11.66 mg/mL at 25°C), enabling preparation of concentrated stock solutions for cell-based assays (APExBIO, link).
For a detailed mechanistic dive and advanced troubleshooting, see this strategic deployment review, which this article extends with updated cell line benchmarks and anti-angiogenic evidence.
Applications, Limits & Misconceptions
Staurosporine is established as a tool compound in:
- Apoptosis induction in cancer cell lines (e.g., A431, THP-1, Mo-7e, CHO-KDR) for quantitative cytotoxicity and signaling studies.
- Inhibition of VEGF-R, PDGF-R, and c-Kit autophosphorylation in receptor tyrosine kinase pathway analysis.
- Modeling anti-angiogenic and anti-metastatic mechanisms in preclinical tumor research.
- Benchmarking new kinase inhibitors via direct comparison to Staurosporine’s broad-spectrum activity.
Common Pitfalls or Misconceptions
- Staurosporine is not selective for a single kinase; broad-spectrum inhibition may confound pathway-specific readouts.
- It does not inhibit autophosphorylation of the insulin, IGF-I, or EGF receptor, limiting its use in those pathways.
- Staurosporine’s high potency means that overdosing can cause non-specific cytotoxicity beyond kinase inhibition.
- Solutions are not stable for long-term storage; fresh preparation is required for reproducibility.
- As an alkaloid, it is for research use only, not for diagnostic or clinical applications.
This article clarifies the above boundaries, updating the scope beyond the mechanistic focus in this prior workflow guide by including anti-angiogenic and in vivo data.
Workflow Integration & Parameters
Staurosporine (SKU: A8192, APExBIO) is supplied as a solid, stored at -20°C. Prepare concentrated stock solutions in DMSO (≥11.66 mg/mL at 25°C). For cell culture, dilute stocks to final concentrations of 0.1–1 μM in assay buffer. Do not store working solutions long-term. Typical incubation time: 24 hours for apoptosis induction in A31, CHO-KDR, Mo-7e, and A431 cells. For animal studies, oral dosing of 75 mg/kg/day has been validated for anti-angiogenic effects. See the full product details for handling and safety at the A8192 kit page.
For advanced, high-throughput microscopy protocols and quantification of fractional killing, see this specialized workflow article, which this article complements with comprehensive kinase and angiogenesis benchmarks.
Conclusion & Outlook
Staurosporine remains the gold-standard broad-spectrum serine/threonine protein kinase inhibitor for cancer research and kinase pathway analysis. Its reproducible, nanomolar potency against PKC isoforms and ability to block VEGF-R autophosphorylation make it indispensable for apoptosis, angiogenesis, and anti-metastatic studies. Key care points include solvent selection, concentration control, and awareness of its broad-spectrum effects. APExBIO provides quality-controlled Staurosporine (SKU: A8192) for validated and translational workflows. Ongoing studies continue to refine its applications and limitations, with new benchmarks for signaling specificity and anti-angiogenic action emerging from both in vitro and in vivo models.